Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: Subgroup analysis of the phase 3 CASTOR and POLLUX studies
- Mateos, M.-V.
- Spencer, A.
- Nooka, A.K.
- Pour, L.
- Weisel, K.
- Cavo, M.
- Laubach, J.P.
- Cook, G.
- Iida, S.
- Benboubker, L.
- Usmani, S.Z.
- Yoon, S.-S.
- Bahlis, N.J.
- Chiu, C.
- Ukropec, J.
- Schecter, J.M.
- Qin, X.
- O'Rourke, L.
- Dimopoulos, M.A.
ISSN: 1592-8721, 0390-6078
Argitalpen urtea: 2020
Alea: 105
Zenbakia: 2
Orrialdeak: 468-477
Mota: Artikulua